Alto Neuroscience (ANRO) Virtual CNS Forum summary

Precision psychiatry approach and platform

• Developed a biomarker-driven platform to match drugs to patient subpopulations using EEG and behavioral measures.

• Focuses on dosing and patient selection based on biomarkers to enhance clinical effect and replicate findings.

• Pipeline includes four assets across depression, bipolar disorder, and schizophrenia, with two in phase IIb and two in earlier stages.

ALTO-100 program insights

• ALTO-100 targets neuroplasticity, especially in patients with hippocampal impairment.

• Phase IIa showed efficacy in biomarker-selected patients; phase IIb failed overall but showed effect in adjunctive group due to compliance issues.

• Noncompliance in monotherapy arm traced to specific sites; compliance verified by blood drug levels.

• Continued development in bipolar depression, with improved site monitoring and internal clinical operations.

Biomarker validation and machine learning

• Biomarkers validated through prospective replication and mechanistic links to drug action.

• EEG biomarker for ALTO-300 developed via machine learning, linked to dopamine function and neural variability.

• Ability to predict placebo response using EEG models, supporting precision approach.